세계 만성 통증 치료 시장은 2023년 976억 달러의 매출을 달성했습니다. 2024년부터 2030년까지 7.4%의 연평균 복합 성장률(CAGR)을 나타내고, 2030년에는 1,596억 달러에 달할 것으로 예측됩니다. 산업 발전의 주요 원인으로는 이러한 솔루션에 대한 정부 지원 확대, 노인 인구 증가, 만성 질환 발생률 증가 등을 꼽을 수 있습니다.
주요 인사이트
중증 두통, 요통, 안면 통증 등 만성 통증 증가로 인해 의약품 카테고리가 약 7.7%의 연평균 복합 성장률(CAGR)로 성장하여 업계 점유율을 주도할 것으로 예상됩니다.
2023년에는 섬유근육통, 골관절염, 류마티스 관절염 등 근골격계 질환이 많이 발생하여 근골격계 카테고리의 점유율이 40%를 차지할 것으로 예상됩니다.
2019-2021년 미국에서는 5,320만 명의 성인이 류마티스 관절염, 통풍, 루푸스, 섬유근육통 등 다양한 유형의 관절염을 앓고 있는 것으로 추정됩니다.
근골격계 분야는 관절염 유병률 증가와 요통이 전 세계적으로 장애를 유발하는 가장 큰 원인으로 꼽히는 등의 요인으로 인해 예측 기간이 끝날 때까지 CAGR 7.3%를 나타낼 것으로 예상됩니다.
적응증별로는 암성 통증 카테고리가 예측 기간 동안 8.0%의 연평균 복합 성장률(CAGR)를 나타낼 전망입니다.
지역별로는 아시아태평양이 의료 인프라 발전, 가처분 소득 증가, 노인 인구 증가, 만성 통증의 확산에 힘입어 예측 기간 동안 7.8%의 연평균 복합 성장률(CAGR)로 가장 빠른 성장세를 보일 것으로 예상됩니다.
2023년에는 북미가 업계 점유율의 55%를 차지할 것으로 예상되며, 발달된 의료 인프라, 높은 의료비, 첨단 통증 치료 솔루션의 광범위한 가용성으로 인해 유리한 입지를 점하고 있습니다.
세계 만성 통증 치료제 시장을 분석했으며, 시장의 기본 구조와 최신 상황, 주요 성장 촉진요인 및 억제요인, 세계 전체 및 지역별/주요 국가별 시장 규모 동향 전망(금액 기준, 2017-2030년), 부문별 상세 동향, 현재 시장 경쟁 구도, 주요 기업 프로파일 등을 조사하여 전해드립니다.
목차
제1장 조사 범위
제2장 조사 방법
제3장 주요 요약
제4장 시장 지표
제5장 업계 전망
시장 역학
동향
성장 촉진요인
성장 억제요인/과제
성장 촉진요인/억제요인의 영향 분석
신형 코로나바이러스(COVID-19)의 영향
Porter의 Five Forces 분석
제6장 세계 시장
개요
시장 매출 : 제품별(2017-2030년)
시장 매출 : 적응증별(2017-2030년)
시장 매출 : 용도별(2017-2030년)
시장 매출 : 유통 채널별(2017-2030년)
시장 매출 : 최종사용자별(2017-2030년)
시장 매출 : 지역별(2017-2030년)
제7장 북미 시장
개요
시장 매출 : 제품별(2017-2030년)
시장 매출 : 적응증별(2017-2030년)
시장 매출 : 용도별(2017-2030년)
시장 매출 : 유통 채널별(2017-2030년)
시장 매출 : 최종사용자별(2017-2030년)
시장 매출 : 국가별(2017-2030년)
제8장 유럽 시장
제9장 아시아태평양 시장
제10장 라틴아메리카 시장
제11장 중동 및 아프리카 시장
제12장 미국 시장
개요
시장 매출 : 제품별(2017-2030년)
시장 매출 : 적응증별(2017-2030년)
시장 매출 : 용도별(2017-2030년)
시장 매출 : 유통 채널별(2017-2030년)
시장 매출 : 최종사용자별(2017-2030년)
제13장 캐나다 시장
제14장 독일 시장
제15장 프랑스 시장
제16장 영국 시장
제17장 이탈리아 시장
제18장 스페인 시장
제19장 일본 시장
제20장 중국 시장
제21장 인도 시장
제22장 호주 시장
제23장 한국 시장
제24장 브라질 시장
제25장 멕시코 시장
제26장 사우디아라비아 시장
제27장 남아프리카공화국 시장
제28장 아랍에미리트(UAE) 시장
제29장 경쟁 구도
시장 진출기업과 제공 제품/서비스 리스트
주요 기업 경쟁 벤치마킹
주요 기업 제품 벤치마킹
최근 전략 전개 상황
제30장 기업 개요
Eli Lilly and Company
GlaxoSmithKline plc
Pfizer Inc.
Medtronic plc
Abbott Laboratories
Boston Scientific Corporation
Novartis AG
Johnson & Johnson Services Inc.
AstraZeneca PLC
Bristol-Myers Squibb Company
Becton, Dickinson and Company
Sanofi S.A.
Teva Pharmaceutical Industries Limited
AbbVie Inc.
Paradigm Biopharmaceuticals Limited
제31장 부록
LSH
영문 목차
영문목차
Market Overview
The chronic pain treatment market achieved a revenue of USD 97.6 billion in 2023 and is projected to experience a compound annual growth rate (CAGR) of 7.4% from 2024 to 2030, reaching USD 159.6 billion by 2030. The major reasons accountable for the development of the industry include the growing government backing for these solutions, increasing elderly populace, and rising occurrence of chronic health conditions.
The industry players have been constantly spending in emerging innovative items for chronic pain treatment. Wearable tech for the treatment of long-lasting pain is one of the major improvements in the chronic pain treatment industry.
The World Health Organization projects a substantial surge in the worldwide populace aged 60 and more from 12% to 22% between 2015 and 2050. This demographic move has augmented the occurrence of chronic pain, mainly among elder patients in nursing homes, posing a challenge for care facilities.
To confront this problem, a combination of pharmacological, non-pharmacological (physical and occupational therapies), and occupational therapies is employed, positively impacting the chronic pain treatment market.
Chronic illnesses such as sickle-cell anemia, osteoarthritis, fibromyalgia, cancer, and autoimmune illnesses such as rheumatoid arthritis are dominant worldwide, requiring therapeutic interventions for better pain management. The extensive use of treatments such as physiotherapy, medication, and psychological therapy reflects the rising load of chronic diseases and their impact on healthcare systems globally.
Key Insights
The drugs category is projected to advance at a CAGR of around 7.7% and lead the industry share because of increasing chronic pain cases such as severe headaches, lower back pain, and facial pain.
Reasons contributing to this development include the growing worldwide elderly populace, sedentary lifestyles, and an increase in surgical procedures.
The need for painkillers is projected to intensify in response to these trends over the forecast period.
In 2023, the musculoskeletal category had a 40% industry share because of the high occurrence of musculoskeletal illnesses such as fibromyalgia, osteoarthritis, and rheumatoid arthritis.
In 2019-2021, as many as 53.2 million U.S. adults had these conditions: different kinds of arthritis (including rheumatoid arthritis), gout, lupus or fibromyalgia, according to NHIS (National Health Interview Survey).
Musculoskeletal segment is predicted to have a CAGR of 7.3% until the end of the forecast period due to some factors e.g. increase arthritis prevalence and back pain which is responsible for disability all over the world being at the top.
During the projection period, the cancer pain category is projected to advance at a CAGR of 8.0% based on indication.
The National Cancer Institute classifies cancer as a principal worldwide reason of death, with forecasts indicating increasing new cases and demises by 2040.
Growing cancer survivor numbers contribute to industry development because of the long-lasting and commonly severe pain related with the disease.
The APAC region is set to be the fastest-growing industry with a CAGR of 7.8% during the projection period, propelled by advancing healthcare infrastructure, increasing disposable income, rising elderly populace, and growing chronic pain prevalence.
Asia's elderly populace is projected to double from 395 million in 2019 to 587 million by 2030, paying to advanced demand for pain treatment medications and devices.
In 2023, the North American region, holding a 55% industry share, advantages from developed healthcare infrastructure, high healthcare spending, and extensive obtainability of advanced pain treatment solutions.
Table of Contents
Chapter 1. Research Scope
1.1. Research Objectives
1.2. Market Definition
1.3. Analysis Period
1.4. Market Size Breakdown by Segments
1.4.1. Market size breakdown, by product
1.4.2. Market size breakdown, by indication
1.4.3. Market size breakdown, by application
1.4.4. Market size breakdown, by distribution channel
1.4.5. Market size breakdown, by end user
1.4.6. Market size breakdown, by region
1.4.7. Market size breakdown, by country
1.5. Market Data Reporting Unit
1.5.1. Value
1.6. Key Stakeholders
Chapter 2. Research Methodology
2.1. Secondary Research
2.1.1. Paid
2.1.2. Unpaid
2.1.3. P&S Intelligence database
2.2. Primary Research
2.3. Market Size Estimation
2.4. Data Triangulation
2.5. Currency Conversion Rates
2.6. Assumptions for the Study
2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Market Indicators
Chapter 5. Industry Outlook
5.1. Market Dynamics
5.1.1. Trends
5.1.2. Drivers
5.1.3. Restraints/challenges
5.1.4. Impact analysis of drivers/restraints
5.2. Impact of COVID-19
5.3. Porter's Five Forces Analysis
5.3.1. Bargaining power of buyers
5.3.2. Bargaining power of suppliers
5.3.3. Threat of new entrants
5.3.4. Intensity of rivalry
5.3.5. Threat of substitutes
Chapter 6. Global Market
6.1. Overview
6.2. Market Revenue, by Product (2017-2030)
6.3. Market Revenue, by Indication (2017-2030)
6.4. Market Revenue, by Application (2017-2030)
6.5. Market Revenue, by Distribution Channel (2017-2030)
6.6. Market Revenue, by End User (2017-2030)
6.7. Market Revenue, by Region (2017-2030)
Chapter 7. North America Market
7.1. Overview
7.2. Market Revenue, by Product (2017-2030)
7.3. Market Revenue, by Indication (2017-2030)
7.4. Market Revenue, by Application (2017-2030)
7.5. Market Revenue, by Distribution Channel (2017-2030)
7.6. Market Revenue, by End User (2017-2030)
7.7. Market Revenue, by Country (2017-2030)
Chapter 8. Europe Market
8.1. Overview
8.2. Market Revenue, by Product (2017-2030)
8.3. Market Revenue, by Indication (2017-2030)
8.4. Market Revenue, by Application (2017-2030)
8.5. Market Revenue, by Distribution Channel (2017-2030)
8.6. Market Revenue, by End User (2017-2030)
8.7. Market Revenue, by Country (2017-2030)
Chapter 9. APAC Market
9.1. Overview
9.2. Market Revenue, by Product (2017-2030)
9.3. Market Revenue, by Indication (2017-2030)
9.4. Market Revenue, by Application (2017-2030)
9.5. Market Revenue, by Distribution Channel (2017-2030)
9.6. Market Revenue, by End User (2017-2030)
9.7. Market Revenue, by Country (2017-2030)
Chapter 10. LATAM Market
10.1. Overview
10.2. Market Revenue, by Product (2017-2030)
10.3. Market Revenue, by Indication (2017-2030)
10.4. Market Revenue, by Application (2017-2030)
10.5. Market Revenue, by Distribution Channel (2017-2030)
10.6. Market Revenue, by End User (2017-2030)
10.7. Market Revenue, by Country (2017-2030)
Chapter 11. MEA Market
11.1. Overview
11.2. Market Revenue, by Product (2017-2030)
11.3. Market Revenue, by Indication (2017-2030)
11.4. Market Revenue, by Application (2017-2030)
11.5. Market Revenue, by Distribution Channel (2017-2030)
11.6. Market Revenue, by End User (2017-2030)
11.7. Market Revenue, by Country (2017-2030)
Chapter 12. U.S. Market
12.1. Overview
12.2. Market Revenue, by Product (2017-2030)
12.3. Market Revenue, by Indication (2017-2030)
12.4. Market Revenue, by Application (2017-2030)
12.5. Market Revenue, by Distribution Channel (2017-2030)
12.6. Market Revenue, by End User (2017-2030)
Chapter 13. Canada Market
13.1. Overview
13.2. Market Revenue, by Product (2017-2030)
13.3. Market Revenue, by Indication (2017-2030)
13.4. Market Revenue, by Application (2017-2030)
13.5. Market Revenue, by Distribution Channel (2017-2030)
13.6. Market Revenue, by End User (2017-2030)
Chapter 14. Germany Market
14.1. Overview
14.2. Market Revenue, by Product (2017-2030)
14.3. Market Revenue, by Indication (2017-2030)
14.4. Market Revenue, by Application (2017-2030)
14.5. Market Revenue, by Distribution Channel (2017-2030)
14.6. Market Revenue, by End User (2017-2030)
Chapter 15. France Market
15.1. Overview
15.2. Market Revenue, by Product (2017-2030)
15.3. Market Revenue, by Indication (2017-2030)
15.4. Market Revenue, by Application (2017-2030)
15.5. Market Revenue, by Distribution Channel (2017-2030)
15.6. Market Revenue, by End User (2017-2030)
Chapter 16. U.K. Market
16.1. Overview
16.2. Market Revenue, by Product (2017-2030)
16.3. Market Revenue, by Indication (2017-2030)
16.4. Market Revenue, by Application (2017-2030)
16.5. Market Revenue, by Distribution Channel (2017-2030)
16.6. Market Revenue, by End User (2017-2030)
Chapter 17. Italy Market
17.1. Overview
17.2. Market Revenue, by Product (2017-2030)
17.3. Market Revenue, by Indication (2017-2030)
17.4. Market Revenue, by Application (2017-2030)
17.5. Market Revenue, by Distribution Channel (2017-2030)
17.6. Market Revenue, by End User (2017-2030)
Chapter 18. Spain Market
18.1. Overview
18.2. Market Revenue, by Product (2017-2030)
18.3. Market Revenue, by Indication (2017-2030)
18.4. Market Revenue, by Application (2017-2030)
18.5. Market Revenue, by Distribution Channel (2017-2030)
18.6. Market Revenue, by End User (2017-2030)
Chapter 19. Japan Market
19.1. Overview
19.2. Market Revenue, by Product (2017-2030)
19.3. Market Revenue, by Indication (2017-2030)
19.4. Market Revenue, by Application (2017-2030)
19.5. Market Revenue, by Distribution Channel (2017-2030)
19.6. Market Revenue, by End User (2017-2030)
Chapter 20. China Market
20.1. Overview
20.2. Market Revenue, by Product (2017-2030)
20.3. Market Revenue, by Indication (2017-2030)
20.4. Market Revenue, by Application (2017-2030)
20.5. Market Revenue, by Distribution Channel (2017-2030)
20.6. Market Revenue, by End User (2017-2030)
Chapter 21. India Market
21.1. Overview
21.2. Market Revenue, by Product (2017-2030)
21.3. Market Revenue, by Indication (2017-2030)
21.4. Market Revenue, by Application (2017-2030)
21.5. Market Revenue, by Distribution Channel (2017-2030)
21.6. Market Revenue, by End User (2017-2030)
Chapter 22. Australia Market
22.1. Overview
22.2. Market Revenue, by Product (2017-2030)
22.3. Market Revenue, by Indication (2017-2030)
22.4. Market Revenue, by Application (2017-2030)
22.5. Market Revenue, by Distribution Channel (2017-2030)
22.6. Market Revenue, by End User (2017-2030)
Chapter 23. South Korea Market
23.1. Overview
23.2. Market Revenue, by Product (2017-2030)
23.3. Market Revenue, by Indication (2017-2030)
23.4. Market Revenue, by Application (2017-2030)
23.5. Market Revenue, by Distribution Channel (2017-2030)
23.6. Market Revenue, by End User (2017-2030)
Chapter 24. Brazil Market
24.1. Overview
24.2. Market Revenue, by Product (2017-2030)
24.3. Market Revenue, by Indication (2017-2030)
24.4. Market Revenue, by Application (2017-2030)
24.5. Market Revenue, by Distribution Channel (2017-2030)
24.6. Market Revenue, by End User (2017-2030)
Chapter 25. Mexico Market
25.1. Overview
25.2. Market Revenue, by Product (2017-2030)
25.3. Market Revenue, by Indication (2017-2030)
25.4. Market Revenue, by Application (2017-2030)
25.5. Market Revenue, by Distribution Channel (2017-2030)
25.6. Market Revenue, by End User (2017-2030)
Chapter 26. Saudi Arabia Market
26.1. Overview
26.2. Market Revenue, by Product (2017-2030)
26.3. Market Revenue, by Indication (2017-2030)
26.4. Market Revenue, by Application (2017-2030)
26.5. Market Revenue, by Distribution Channel (2017-2030)
26.6. Market Revenue, by End User (2017-2030)
Chapter 27. South Africa Market
27.1. Overview
27.2. Market Revenue, by Product (2017-2030)
27.3. Market Revenue, by Indication (2017-2030)
27.4. Market Revenue, by Application (2017-2030)
27.5. Market Revenue, by Distribution Channel (2017-2030)
27.6. Market Revenue, by End User (2017-2030)
Chapter 28. U.A.E. Market
28.1. Overview
28.2. Market Revenue, by Product (2017-2030)
28.3. Market Revenue, by Indication (2017-2030)
28.4. Market Revenue, by Application (2017-2030)
28.5. Market Revenue, by Distribution Channel (2017-2030)
